SAB Biotherapeutics (SABS) EBITDA Margin (2021 - 2024)
SAB Biotherapeutics (SABS) posted EBITDA Margin of 8726.26% for Q4 2024, down 125.08% on a QoQ basis from 3876.95% in Q2 2024, and down 253836.0% year-over-year from N/an in Q1 2024.
SAB Biotherapeutics (SABS) EBITDA Margin (2021 - 2024) Analysis & Trends
SAB Biotherapeutics' EBITDA Margin history runs 4 years deep, the most recent figure standing at 8726.26% for Q4 2024.
- Quarterly EBITDA Margin fell 253836.0% year-over-year to 8726.26% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 3244.87% (down 154432.0% YoY) and the FY2024 annual result came in at 3244.87%, down 154432.0% from the prior year.
- EBITDA Margin was 8726.26% for Q4 2024 at SAB Biotherapeutics, down from 3876.95% in the prior quarter.
- Across five years, EBITDA Margin topped out at 4.81% in Q1 2021 and bottomed at 8726.26% in Q4 2024.
- A 4-year average of 2007.32% and a median of 363.74% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin slumped 747037 bps — and 2024, when it soared 369644 bps.
- SAB Biotherapeutics' EBITDA Margin stood at 66.41% in 2021, then slumped by 448 bps to 363.74% in 2022, then sank by 1601 bps to 6187.9% in 2023, then tumbled by 41 bps to 8726.26% in 2024.
- Business Quant data shows SABS's EBITDA Margin at 8726.26% in Q4 2024, 3876.95% in Q2 2024, and 1205.9% in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -8,726.26% |
| Jun 30, 2024 | -3,876.95% |
| Mar 31, 2024 | -1,205.90% |
| Dec 31, 2023 | -6,187.90% |
| Sep 30, 2023 | -420.00% |
| Jun 30, 2023 | -7,573.40% |
| Mar 31, 2023 | -1,273.79% |
| Dec 31, 2022 | -363.74% |
| Sep 30, 2022 | -217.49% |
| Jun 30, 2022 | -103.03% |
| Mar 31, 2022 | -56.83% |
| Dec 31, 2021 | -66.41% |
| Sep 30, 2021 | -27.18% |
| Jun 30, 2021 | -15.77% |
| Mar 31, 2021 | 4.81% |